Bayer Healthcare Company Profile
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
What is the competitive landscape for BAYER HEALTHCARE, and what generic alternatives to BAYER HEALTHCARE drugs are available?
BAYER HEALTHCARE has twenty-nine approved drugs.
There are twenty-six US patents protecting BAYER HEALTHCARE drugs. There is one tentative approval on BAYER HEALTHCARE drugs.
There are four hundred and ten patent family members on BAYER HEALTHCARE drugs in fifty-eight countries and forty-seven supplementary protection certificates in seventeen countries.
Summary for Bayer Healthcare
International Patents: | 410 |
US Patents: | 26 |
Tradenames: | 24 |
Ingredients: | 14 |
NDAs: | 29 |
Patent Litigation for Bayer Healthcare: | See patent lawsuits for Bayer Healthcare |
Drugs and US Patents for Bayer Healthcare
Expired US Patents for Bayer Healthcare
International Patents for Bayer Healthcare Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Spain | 2588504 | See Plans and Pricing |
Croatia | P20131159 | See Plans and Pricing |
Chile | 2017001249 | See Plans and Pricing |
Cyprus | 1109790 | See Plans and Pricing |
Russian Federation | 2751636 | See Plans and Pricing |
Taiwan | 201249847 | See Plans and Pricing |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Bayer Healthcare Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
3141251 | 301099 | Netherlands | See Plans and Pricing | PRODUCT NAME: A MEDICINAL PRODUCT CONSISTING OF A COMBINATION OF A FIRST DOSE PHARMACEUTICAL COMPOSITION AND A SECOND DOSE PHARMACEUTICAL COMPOSITION, THE FIRST DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, SODIUM SULPHATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE AND THE SECOND DOSE PHARMACEUTICAL COMPOSITION CONSISTING OF THE ACTIVE INGREDIENTS POLYETHYLENE GLYCOL, ASCORBIC ACID, SODIUM ASCORBATE, SODIUM CHLORIDE AND POTASSIUM CHLORIDE; NATIONAL REGISTRATION NO/DATE: RVG 120195 20171114; FIRST REGISTRATION: IS IS/1/17/083/01 20171016 |
2493858 | C02493858/01 | Switzerland | See Plans and Pricing | PRODUCT NAME: DAROLUTAMIDUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67521 19.06.2020 |
3106463 | 2090009-8 | Sweden | See Plans and Pricing | PRODUCT NAME: LAROTRECTINIB,OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, PARTICULARLY LAROTRECTINIB SULFATE INCLUDING LAROTRECTINIB HYDROGEN SULFATE; REG. NO/DATE: EU/1/19/1385 20190923 |
2493858 | 301041 | Netherlands | See Plans and Pricing | PRODUCT NAME: DAROLUTAMIDE, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN OF IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBARE ESTER DAARVAN; REGISTRATION NO/DATE: EU/1/20/1432 20200330 |
3106463 | 132020000000025 | Italy | See Plans and Pricing | PRODUCT NAME: LAROTRECTINIB E/O SUOI SALI FARMACEUTICAMENTE ACCETTABILI, IN PARTICOLARE LAROTRECTINIB SOLFATO INCLUSO LAROTRECTINIB IDROGENO SOLFATO(VITRAKVI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1385, 20190923 |
3106463 | 2020C/507 | Belgium | See Plans and Pricing | PRODUCT NAME: VITRAKVI - LAROTRECTINIB ET/OU SES SELS ACCEPTABLES EN PHARMACIE, EN PARTICULIER L'HYDROGENO SULFATE DE LAROTRECTINIB; AUTHORISATION NUMBER AND DATE: EU/1/19/1385 20190923 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.